Natus Medical Upgraded by Zacks to “Outperform” (BABY)
Natus Medical (NASDAQ:BABY) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued on Tuesday, Stock Ratings Network reports. The firm currently has a $15.40 target price on the stock. Zacks‘ target price would suggest a potential upside of 6.35% from the company’s current price.
Natus Medical (NASDAQ:BABY) traded up 2.12% during mid-day trading on Tuesday, hitting $14.48. 156,580 shares of the company’s stock traded hands. Natus Medical has a one year low of $9.65 and a one year high of $15.18. The stock’s 50-day moving average is $13.64 and its 200-day moving average is $13.4. The company has a market cap of $433.7 million and a price-to-earnings ratio of 40.51.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.07. The company had revenue of $82.30 million for the quarter, compared to the consensus estimate of $83.50 million. During the same quarter in the previous year, the company posted $0.12 earnings per share. The company’s revenue for the quarter was up 34.9% on a year-over-year basis. On average, analysts predict that Natus Medical will post $0.79 earnings per share for the current fiscal year.
A number of other firms have also recently commented on BABY. Analysts at Roth Capital cut their price target on shares of Natus Medical (NASDAQ:BABY) from $17.00 to $15.00 in a research note to investors on Tuesday, July 9th. They now have a “buy” rating on the stock. Analysts at Raymond James cut their price target on shares of Natus Medical (NASDAQ:BABY) from $17.00 to $15.00 in a research note to investors on Tuesday, July 9th. They now have an “outperform” rating on the stock.
Natus Medical Incorporated (NASDAQ:BABY) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.